Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital

Intellia Therapeutics (NTLA) Misses Q2 EPS by 30c

August 8, 2024 7:30 AM EDT

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.52), $0.30 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $6.96 million versus the consensus estimate of $19.68 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

... More